🇺🇸 FDA
Patent

US 9617203

Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

granted A61KA61K31/133A61K31/165

Quick answer

US patent 9617203 (Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide) held by VANDA PHARMACEUTICALS INC. expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VANDA PHARMACEUTICALS INC.
Grant date
Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/133, A61K31/165, A61P, A61P15/00